Biohaven Pharmaceutical Holding Company Insights
Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.
A sample of Biohaven Pharmaceutical Holding Company Insights data
Headline | Published | Journalists |
---|---|---|
Deserunt mollit sunt Lorem laborum do id aliqua dolore | 30 Nov 2022 | Lorem |
ALS drug trial readouts to watch in 2022 | 10 Jan 2022 | William Newton |
AbbVie’s atogepant, Biohaven’s Nurtec ODT for preventive migraine may not cause approved mAbs as many headaches as market expects, experts say | 23 Apr 2021 | William Newton |
Biohaven’s zavegepant has potential positive impact in Phase II COVID-19 study though broad MOA, limited understanding of immune system's role raises some expert concern | 07 Oct 2020 | William Newton |
Feature
Delivers exclusive investigative journalist content including breaking news and analysis ahead of market-moving events.
Benefit
Drug Insights:
- Forward-looking, nuanced, qualitative asset analysis on development, approval & market/reimbursement potential
- Material intelligence on competitors, including breaking news
- Insight on companies’ business development needs and strategies
Outsourcing Insights:
Insight on companies’ CRO and business development needs, strategies and relationships
Value
Remove risk and uncertainty
Gain a competitive edge
Secure actionable leads
Premium databases is part of our industry range of products
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward